Cardiff Oncology 2025 Q3 Earnings Narrows Loss, Beats Revenue Estimates

Cardiff Oncology (CRDF) reported Q3 2025 results that outperformed expectations, with a narrower net loss and revenue exceeding forecasts. The company’s cash runway now extends into Q1 2027, supported by $60.6 million in liquidity, and its Phase 2 CRDF-004 trial showed 19% higher confirmed ORR for onvansertib in RAS-mutated mCRC.

Revenue

, . The drop reflects ongoing challenges in generating consistent revenue streams, though the company exceeded Wall Street’s $121,430 revenue estimate.

Earnings/Net Income

The company narrowed its net loss to $11.26 million, or $0.17 per share, . , the company has posted losses for 15 consecutive years, underscoring persistent financial challenges despite recent progress.

Price Action

, with a 0.45% gain month-to-date. The post-earnings strategy of buying shares on the revenue announcement date and holding for 30 days yielded a 25.8% gain, slightly underperforming the NASDAQ Composite’s 26.9% return. This suggests a viable short-term strategy, though broader market momentum remains stronger.

Post-Earnings Price Action Review

, . This indicates that while the stock’s short-term performance aligns with its clinical progress, particularly the CRDF-004 trial data, the broader market’s gains highlight structural headwinds for biotech firms. .

CEO Commentary

CEO emphasized “highly encouraging” CRDF-004 trial data, . He highlighted the drug’s potential to redefine first-line care for RAS-mutated mCRC, . . , , .

Guidance

, . , , . , though risks like clinical delays or regulatory hurdles remain.

Additional News

Cardiff Oncology’s leadership highlighted positive Phase 2 CRDF-004 trial data, . . , offering insights into the drug’s development and commercial potential. Additionally, the company appointed Dr. as Chief Medical Officer, .